Intervention Review

You have free access to this content

Once or twice daily versus three times daily amoxicillin with or without clavulanate for the treatment of acute otitis media

  1. Sanguansak Thanaviratananich1,*,
  2. Malinee Laopaiboon2,
  3. Patravoot Vatanasapt1

Editorial Group: Cochrane Acute Respiratory Infections Group

Published Online: 13 DEC 2013

Assessed as up-to-date: 15 MAR 2013

DOI: 10.1002/14651858.CD004975.pub3


How to Cite

Thanaviratananich S, Laopaiboon M, Vatanasapt P. Once or twice daily versus three times daily amoxicillin with or without clavulanate for the treatment of acute otitis media. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD004975. DOI: 10.1002/14651858.CD004975.pub3.

Author Information

  1. 1

    Faculty of Medicine, Khon Kaen University, Department of Otorhinolaryngology, Khon Kaen, Thailand

  2. 2

    Khon Kaen University, Department of Biostatistics and Demography, Faculty of Public Health, Khon Kaen, Thailand

*Sanguansak Thanaviratananich, Department of Otorhinolaryngology, Faculty of Medicine, Khon Kaen University, 123 Friendship Road, Khon Kaen, 40002, Thailand. sthanaviratananich@gmail.com. sanguansak2011@gmail.com.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 13 DEC 2013

SEARCH

[Figure 1]
Figure 1. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 2]
Figure 2. Funnel plot of the five trials included.
[Figure 3]
Figure 3. Forest plot of comparison: Clinical cure rate at the end of therapy.
[Figure 4]
Figure 4. Forest plot of comparison: Clinical cure rate during therapy.
[Figure 5]
Figure 5. Forest plot of comparison: Clinical cure at post-treatment (one to three months).
[Figure 6]
Figure 6. Forest plot of comparison: AOM complications: Recurrent AOM after completion of therapy.
[Analysis 1.1]
Analysis 1.1. Comparison 1 One or two daily doses versus three daily doses, Outcome 1 Clinical cure rate at the end of therapy.
[Analysis 1.2]
Analysis 1.2. Comparison 1 One or two daily doses versus three daily doses, Outcome 2 Clinical cure rate during therapy.
[Analysis 1.3]
Analysis 1.3. Comparison 1 One or two daily doses versus three daily doses, Outcome 3 Clinical cure rate at post-treatment.
[Analysis 1.4]
Analysis 1.4. Comparison 1 One or two daily doses versus three daily doses, Outcome 4 AOM complications: Recurrent AOM after completion of therapy.
[Analysis 1.5]
Analysis 1.5. Comparison 1 One or two daily doses versus three daily doses, Outcome 5 Adverse reactions to medication (overall).
[Analysis 1.6]
Analysis 1.6. Comparison 1 One or two daily doses versus three daily doses, Outcome 6 Specific adverse reactions to medication: Diarrhoea.
[Analysis 1.7]
Analysis 1.7. Comparison 1 One or two daily doses versus three daily doses, Outcome 7 Specific reactions to medication: Skin adverse events.
[Analysis 1.8]
Analysis 1.8. Comparison 1 One or two daily doses versus three daily doses, Outcome 8 Compliance rate.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Analysis for amoxicillin treatment trials only, Outcome 1 Clinical cure rate at the end of therapy.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Analysis for amoxicillin treatment trials only, Outcome 2 Clinical cure rate during therapy.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Analysis for amoxicillin treatment trials only, Outcome 3 Clinical cure rate at post-treatment.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Analysis for amoxicillin treatment trials only, Outcome 4 AOM complications: Recurrent AOM after completion of therapy.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Analysis for amoxicillin treatment trials only, Outcome 5 Specific adverse reactions to medication: Diarrhoea.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Analysis for amoxicillin treatment trials only, Outcome 6 Specific adverse reactions to medication: Skin adverse events.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Analysis for amoxicillin treatment trials only, Outcome 7 Compliance rate.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Analysis for amoxicillin/clavulanate treatment trials only, Outcome 1 Clinical cure rate at the end of therapy.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Analysis for amoxicillin/clavulanate treatment trials only, Outcome 2 Clinical cure rate during therapy.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Analysis for amoxicillin/clavulanate treatment trials only, Outcome 3 Clinical cure rate at post-treatment.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Analysis for amoxicillin/clavulanate treatment trials only, Outcome 4 AOM complications: Recurrent AOM after completion of therapy.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Analysis for amoxicillin/clavulanate treatment trials only, Outcome 5 Adverse reactions to medication: Overall.
[Analysis 3.6]
Analysis 3.6. Comparison 3 Analysis for amoxicillin/clavulanate treatment trials only, Outcome 6 Specific adverse reactions of medication: Diarrhoea.
[Analysis 3.7]
Analysis 3.7. Comparison 3 Analysis for amoxicillin/clavulanate treatment trials only, Outcome 7 Specific adverse reactions to medication: Skin adverse events.
[Analysis 3.8]
Analysis 3.8. Comparison 3 Analysis for amoxicillin/clavulanate treatment trials only, Outcome 8 Compliance rate.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Analysis excluding the studies with many unclear risk of bias characteristics (Principi 1986), Outcome 1 Clinical cure rate at the end of therapy.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Analysis excluding the studies with many unclear risk of bias characteristics (Principi 1986), Outcome 2 Clinical cure rate during therapy.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Analysis excluding the studies with many unclear risk of bias characteristics (Principi 1986), Outcome 3 AOM complications: Recurrent AOM after completion of therapy.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Analysis excluding the studies with many unclear risk of bias characteristics (Principi 1986), Outcome 4 Adverse reactions to medication: Overall adverse events.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Analysis excluding the studies with many unclear risk of bias characteristics (Principi 1986), Outcome 5 Specific adverse reactions to medication: Diarrhoea.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Analysis excluding the studies with many unclear risk of bias characteristics (Principi 1986), Outcome 6 Specific adverse events to medication: Skin adverse events.